[go: up one dir, main page]

TN2013000471A1 - Cycloalkyl-fused tetrahydroquinolines as crth2 receptor modulators - Google Patents

Cycloalkyl-fused tetrahydroquinolines as crth2 receptor modulators

Info

Publication number
TN2013000471A1
TN2013000471A1 TNP2013000471A TN2013000471A TN2013000471A1 TN 2013000471 A1 TN2013000471 A1 TN 2013000471A1 TN P2013000471 A TNP2013000471 A TN P2013000471A TN 2013000471 A TN2013000471 A TN 2013000471A TN 2013000471 A1 TN2013000471 A1 TN 2013000471A1
Authority
TN
Tunisia
Prior art keywords
cycloalkyl
receptor modulators
crth2 receptor
tetrahydroquinolines
fused
Prior art date
Application number
TNP2013000471A
Other languages
English (en)
Inventor
Xianhai Huang
Jason Brubaker
Scott L Peterson
John W Butcher
Joshua T Close
Michelle Martinez
Rachel Nicola Maccoss
Joon O Jung
Phieng Siliphaivanh
Hongjun Zhang
Robert G Aslanian
Purakkattle Johny Biju
Li Dong
Ying Huang
Kevin D Mccormick
Anandan Palani
Ning Shao
Wei Zhou
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47357455&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2013000471(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of TN2013000471A1 publication Critical patent/TN2013000471A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
TNP2013000471A 2011-06-17 2013-11-13 Cycloalkyl-fused tetrahydroquinolines as crth2 receptor modulators TN2013000471A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161498345P 2011-06-17 2011-06-17
PCT/US2012/042336 WO2012174176A1 (fr) 2011-06-17 2012-06-14 Tétrahydroquinolines à fusion cycloalkyle en tant que modulateurs de l'activité du récepteur crth2

Publications (1)

Publication Number Publication Date
TN2013000471A1 true TN2013000471A1 (en) 2015-03-30

Family

ID=47357455

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2013000471A TN2013000471A1 (en) 2011-06-17 2013-11-13 Cycloalkyl-fused tetrahydroquinolines as crth2 receptor modulators

Country Status (26)

Country Link
US (2) US20140128367A1 (fr)
EP (1) EP2720545B1 (fr)
JP (1) JP5629403B2 (fr)
KR (1) KR101599157B1 (fr)
CN (1) CN103763924B (fr)
AR (1) AR086931A1 (fr)
AU (1) AU2012271661B8 (fr)
BR (1) BR112013032557A2 (fr)
CA (1) CA2838731C (fr)
CL (1) CL2013003625A1 (fr)
CO (1) CO6821958A2 (fr)
CR (1) CR20130670A (fr)
DO (1) DOP2013000306A (fr)
EA (1) EA025100B1 (fr)
EC (1) ECSP14013156A (fr)
ES (1) ES2613644T3 (fr)
IL (1) IL229508A0 (fr)
MA (1) MA35188B1 (fr)
MX (1) MX2013014900A (fr)
NI (1) NI201300133A (fr)
PE (1) PE20140788A1 (fr)
PH (1) PH12013502619A1 (fr)
TN (1) TN2013000471A1 (fr)
TW (1) TW201302711A (fr)
WO (1) WO2012174176A1 (fr)
ZA (1) ZA201308942B (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2661428B1 (fr) 2010-12-23 2017-06-07 Merck Sharp & Dohme Corp. Peptides de liaison à her2 marqués par un composé organosilicium contenant 18f
US9290453B2 (en) 2010-12-23 2016-03-22 Merck Sharp & Dohme Corp. Quinolines and aza-quinolines as CRTH2 receptor modulators
US9290454B2 (en) 2012-10-01 2016-03-22 Merck Sharp & Dohme Corp. Substituted isoquinolines as CRTH2 receptor modulators
CN104761437B (zh) * 2015-03-31 2018-06-19 上海康鹏化学有限公司 一种4-溴-2,6-二氟三氟甲氧基苯的制备方法
CN104829556B (zh) * 2015-05-06 2018-01-23 南京信息工程大学 一种由固体光气和氨基硫脲反应制备2‑羟基‑5‑氨基‑1,3,4‑噻二唑的方法
CN107849041B (zh) 2015-07-23 2021-07-23 默沙东公司 与对crth2受体拮抗剂的反应有关的遗传标记
WO2017209272A1 (fr) * 2016-06-03 2017-12-07 国立大学法人東京大学 Inhibiteur de métastases cancéreuses
WO2024124287A1 (fr) * 2022-12-12 2024-06-20 The Walter And Eliza Hall Institute Of Medical Research Composés pour traiter une infection virale

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995015973A1 (fr) 1993-12-06 1995-06-15 Cytel Corporation Peptidomimetiques cs-1, compositions et procedes pour les utiliser
US5510332A (en) 1994-07-07 1996-04-23 Texas Biotechnology Corporation Process to inhibit binding of the integrin α4 62 1 to VCAM-1 or fibronectin and linear peptides therefor
AU2964295A (en) 1994-07-11 1996-02-09 Athena Neurosciences, Inc. Inhibitors of leukocyte adhesion
US5811391A (en) 1994-08-25 1998-09-22 Cytel Corporation Cyclic CS-1 peptidomimetics, compositions and methods of using same
GB9524630D0 (en) 1994-12-24 1996-01-31 Zeneca Ltd Chemical compounds
US6306840B1 (en) 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
WO1996031206A2 (fr) 1995-04-07 1996-10-10 Warner-Lambert Company Flavones et coumarines utilisees en tant qu'agents dans le traitement de l'atherosclerose
WO1996040781A1 (fr) 1995-06-07 1996-12-19 Tanabe Seiyaku Co., Ltd. INHIBITEURS PEPTIDIQUES CYCLIQUES D'ADHERENCE CELLULAIRE INDUITE PAR INTEGRINE β1 ET β¿2?
AU6311996A (en) 1995-07-06 1997-02-05 Zeneca Limited Peptide inhibitors of fibronectine
US6248713B1 (en) 1995-07-11 2001-06-19 Biogen, Inc. Cell adhesion inhibitors
US5925527A (en) * 1997-02-04 1999-07-20 Trega Biosciences, Inc. Tricyclic Tetrahydroquinoline derivatives and tricyclic tetrahydroquinoline combinatorial libraries
GT199900147A (es) 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
ES2277853T3 (es) * 1999-10-14 2007-08-01 Kaken Pharmaceutical Co., Ltd. Derivados de tetrahidroquinolina.
FR2825092B1 (fr) 2001-05-23 2005-01-14 Servier Lab Nouveau derives trycicliques de dihydro-quinoleines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2827206B1 (fr) 2001-07-10 2004-04-02 Nature Bois Emballages Procede et dispositif de formage de planchettes, et emballages comportant de telles planchettes
US7534897B2 (en) * 2002-05-16 2009-05-19 Shionogi & Co., Ltd. Indole arylsulfonaimide compounds exhibiting PGD 2 receptor antagonism
EP1556047A4 (fr) 2002-10-04 2009-09-30 Millennium Pharm Inc Antagonistes vis-a-vis du recepteur pgd2 pour le traitement de maladies inflammatoires
US7504508B2 (en) 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
WO2004035541A1 (fr) 2002-10-15 2004-04-29 Janssen Pharmaceutica, N.V. Derives (piperidine-4-yl)-aminobenzamido a substitution benzyl servant de modulateurs de recepteurs delta-opioides
CA2500083A1 (fr) 2002-10-21 2004-04-29 Warner-Lambert Company Llc Derives de tetrahydroquinoline antagonistes de crth2
KR20060016817A (ko) 2003-06-20 2006-02-22 콜리 파마슈티칼 게엠베하 소분자 톨-유사 수용체 (ｔｌｒ) 길항제
WO2005007094A2 (fr) 2003-07-09 2005-01-27 Tularik Inc. Modulateurs d'asthme et d'inflammations allergiques
KR20070002085A (ko) 2004-04-07 2007-01-04 밀레니엄 파머슈티컬스 인코퍼레이티드 염증 질병을 치료하기 위한 ｐｇｄ２ 수용체 길항제
PT1833791E (pt) * 2004-12-27 2011-10-19 Actelion Pharmaceuticals Ltd Derivados de 2,3,4,9-tetra-hidro-1h-carbazol como antgonistas do receptor crth2
CN101146776A (zh) * 2005-02-24 2008-03-19 米伦纽姆医药公司 治疗炎性疾病的pgd2受体拮抗剂
JP4972644B2 (ja) 2005-08-12 2012-07-11 メルク カナダ インコーポレイテッド Ｃｒｔｈ２受容体拮抗薬としてのインドール誘導体
JP2012502927A (ja) 2008-09-22 2012-02-02 メルク カナダ インコーポレイテッド Ｃｒｔｈ２受容体拮抗薬としてのインドール誘導体
CA2736571A1 (fr) * 2008-09-22 2010-03-25 Merck Frosst Canada Ltd. Derives d'azaindole comme antagonistes du recepteur crth2
CA2737460C (fr) 2008-09-22 2016-12-20 Merck Frosst Canada Ltd. Derives d'indole utilisables en tant qu'antagonistes du recepteur crth2
MX2011008869A (es) * 2009-02-24 2011-12-16 Merck Sharp & Dohme Derivados de indol como antagonistas del receptor de la molecula homologa a receptor de quimioatrayente expresada en celulas th2.
EP2627178B1 (fr) 2010-10-11 2018-05-02 Merck Sharp & Dohme Corp. Composés de type quinazolinone convenant comme antagonistes de crth2
US9290453B2 (en) 2010-12-23 2016-03-22 Merck Sharp & Dohme Corp. Quinolines and aza-quinolines as CRTH2 receptor modulators
EP2661428B1 (fr) 2010-12-23 2017-06-07 Merck Sharp & Dohme Corp. Peptides de liaison à her2 marqués par un composé organosilicium contenant 18f

Also Published As

Publication number Publication date
WO2012174176A1 (fr) 2012-12-20
US20140128367A1 (en) 2014-05-08
JP2014517041A (ja) 2014-07-17
AU2012271661A8 (en) 2016-11-10
ES2613644T3 (es) 2017-05-25
US20120329743A1 (en) 2012-12-27
EA025100B1 (ru) 2016-11-30
CA2838731C (fr) 2016-08-16
ZA201308942B (en) 2015-05-27
CN103763924B (zh) 2016-05-18
JP5629403B2 (ja) 2014-11-19
CN103763924A (zh) 2014-04-30
MA35188B1 (fr) 2014-06-02
KR101599157B1 (ko) 2016-03-02
AU2012271661A1 (en) 2014-01-16
CR20130670A (es) 2014-02-04
PH12013502619A1 (en) 2014-02-17
IL229508A0 (en) 2014-01-30
TW201302711A (zh) 2013-01-16
CO6821958A2 (es) 2013-12-31
BR112013032557A2 (pt) 2020-09-24
AR086931A1 (es) 2014-01-29
CA2838731A1 (fr) 2012-12-20
MX2013014900A (es) 2014-02-17
EP2720545A1 (fr) 2014-04-23
AU2012271661B8 (en) 2016-11-10
CL2013003625A1 (es) 2014-08-01
KR20140025576A (ko) 2014-03-04
EA201490031A1 (ru) 2014-12-30
EP2720545B1 (fr) 2016-11-30
AU2012271661B2 (en) 2016-11-03
ECSP14013156A (es) 2014-02-28
DOP2013000306A (es) 2014-06-01
EP2720545A4 (fr) 2015-01-14
NI201300133A (es) 2014-02-28
PE20140788A1 (es) 2014-07-09
US8592383B2 (en) 2013-11-26

Similar Documents

Publication Publication Date Title
MX2013007295A (es) Quinoxalinas y aza-quinoxalinas como moduladores del receptor de crth2.
TN2013000471A1 (en) Cycloalkyl-fused tetrahydroquinolines as crth2 receptor modulators
PH12018500960A1 (en) Processes for preparing isoquinolinones and solid forms of isoquinolinones
PH12014500468A1 (en) Heterocyclic compounds and uses thereof
AU2012284088A8 (en) Heterocyclic compounds and uses thereof
IN2014MN02598A (fr)
EA033281B1 (ru) Азабензимидазолы и их применение в качестве модуляторов рецептора ampa
PH12016502378A1 (en) Substituted dihydroisoquinolinone compounds
MX2014012695A (es) Derivados de isoindolona.
EA033544B1 (ru) Производные пиридона в качестве ингибиторов киназы, реаранжированной во время трансфекции (ret)
MD20140063A2 (ro) Derivaţi de acid benzotiazol-6-il acetic şi utilizarea acestora pentru tratarea unei infecţii HIV
PH12015501363A1 (en) Chloro-pyrazine carboxamide derivatives with epithelial sodium channel blocking activity
MX349556B (es) Derivados de aminopirimidina como moduladores de proteina cinasa 2 rica en unidades repetitivas de leucina (lrrk2).
MX2013008431A (es) Antagonista del receptor de mineralocorticoides.
TW201613864A (en) Novel compounds
TN2013000346A1 (en) Asymmetric ureas and medical uses thereof
IN2014DN06869A (fr)
MX337849B (es) Composiciones y metodos para inhibicion de la via jak.
MX2017013877A (es) Compuestos de benzimidazolona y benzotiazolona y su uso como moduladores del receptor ampa.
IN2014DN07636A (fr)
MD20160111A2 (ro) Derivaţi diheterociclici legaţi de cicloalchil
MX2013009386A (es) Nuevos compuestos de azaespirodecanona.
HK1219723A1 (zh) 作为前动力蛋白受体调节剂的派啶和氮杂䓬衍生物
MX369806B (es) Compuestos de indolona y su uso como moduladores del receptor ampa.
TN2013000150A1 (en) Co-crystals and salts of ccr3-inhibitors